SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing heightened market activity as the community anticipates the upcoming Goliath mainnet launch. Traders are actively debating whether this momentum represents a sustainable bullish breakout or another cycle of volatility, with many monitoring whale movements and network infrastructure preparations while maintaining strong conviction in long-term staking.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is seeing significant market interest as community members speculate on its integration with AI authentication and its role as a potential standard for human verification. Traders are actively tracking institutional treasury accumulation and the broader strategic involvement of high-profile figures in the AI sector, driving discussions around its long-term adoption and price potential.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is experiencing significant momentum as the community focuses on its upcoming halving and growing institutional interest, with many investors highlighting its role as a leading decentralized AI infrastructure network. Discussions are heavily centered on the potential for long-term growth driven by scarcity, the ecosystem's unique incentive structure for AI subnets, and active accumulation ahead of expected supply changes.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is experiencing heightened volatility and intense community debate as investors weigh the project's long-term potential in agentic AI against significant recent downward price pressure. While some see the current levels as a compelling accumulation opportunity driven by robust fundamentals and institutional interest, others are expressing frustration over stagnant performance and the lasting impact of the ASI merger and recent token liquidations.

Dogelon Mars

Dogelon Mars is seeing renewed community engagement, with many long-term holders debating whether to continue holding or divest as they watch for potential shifts in the broader meme coin market. While some investors express frustration over price volatility and perceived lack of utility, the community remains polarized, with many discussing the potential for a rebound tied to overall market cycles and crypto-friendly political developments.

ONEOK, Inc. engages in gathering, processing, fractionating, transporting, storing and marketing of natural gas. It operates through the following segments: Natural Gas Gathering and Processing, Natural Gas Liquids and Natural Gas Pipelines. The Natural Gas Gathering and Processing segment offers midstream services to producers in North Dakota, Montana, Wyoming, Kansas and Oklahoma. The Natural Gas Liquids segment owns and operates facilities that gather, fractionate, treat and distribute NGLs and store NGL products, in Oklahoma, Kansas, Texas, New Mexico and the Rocky Mountain region, which includes the Williston, Powder River and DJ Basins, where it provides midstream services to producers of NGLs and deliver those products to the two market centers, one in the Mid-Continent in Conway, Kansas and the other in the Gulf Coast in Mont Belvieu, Texas. The Natural Gas Pipelines segment provides transportation and storage services to end users. The company was founded in 1906 and is headquartered in Tulsa, OK.

Oneok Inc.

ONEOK is actively trending as investors analyze the company's recent strategic acquisitions and their integration within its midstream operations, which remain a primary focus for the market. The community is heavily engaged in debating the stock's long-term growth potential and dividend consistency, while watching for technical breakouts amid fluctuations in natural gas liquids volume and market-wide energy sector volatility.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is seeing intense investor focus as the company's NDA for CTx-1301 was officially accepted by the FDA, setting a PDUFA date of May 31, 2026. The community is buzzing over the potential for an upcoming U.S. patent grant and the possibility of a buyout, with many long-term holders actively accumulating shares and debating the stock's potential for significant upside as it nears commercialization.

Shell Plc engages in the business of producing oil and natural gas. It operates through the following segments: Integrated Gas, Upstream, Marketing, Chemicals and Products, Renewables and Energy Solutions, and Corporate. The Integrated Gas segment includes liquefied natural gas, and conversion of natural gas into gas-to-liquids fuels. The Upstream segment focuses on exploration and extraction of crude oil, natural gas, and natural gas liquids. The Marketing segment is involved in mobility, lubricants, and sectors and decarbonization businesses. The Chemicals and Products segment consists of chemicals manufacturing plants with marketing network and refineries, which turn crude oil and other feedstocks into a range of oil products. The Renewables and Energy Solutions segment provides renewable power generation, marketing, trading, and optimizing power and pipeline gas, as well as carbon credits and digitally enabled customer solutions. The Corporate segment covers non-operating activities supporting Shell such as holdings, treasury organization, self-insurance activities, and headquarters and central functions. The company was founded in February 1907 and is headquartered in London, the United Kingdom.

Shell Plc - ADR (Representing - Ordinary Shares)

Shell Plc is capturing significant investor interest as global energy markets react to intensifying geopolitical volatility and potential supply chain disruptions. The community is actively discussing the company's role as a dominant global LNG trader, its massive share buyback programs, and strategic portfolio shifts, including recent asset divestments and expansion in high-return energy projects.

VanEck ETF Trust - VanEck Junior Gold Miners ETF

VanEck Junior Gold Miners ETF

The VanEck Junior Gold Miners ETF (GDXJ) is experiencing significant market interest and volatility as investors debate the impact of current gold price trends, inflationary pressures, and broader economic uncertainty. Community discussion is heavily focused on whether this rally represents a long-term shift for the mining sector or a potential peak, with many traders closely monitoring Elliott Wave structures and margin call risks while others express conviction in the sector as a strategic hedge.

United States Commodity Funds LLC - United States 12 Month Natural Gas Fund

United States 12 Month Natural Gas

Investors are closely monitoring UNL as the community debates the long-term outlook for natural gas, with many highlighting the risks associated with the steep contango curve and decay in related ETFs. Discussions are centered on geopolitical risks and the ongoing balance between supply-side production levels and seasonal demand shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seres Therapeutics (NASDAQ:MCRB) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group restated a "buy" rating and issued a $22.00 price target on shares of Seres Therapeutics in a research report on Friday...

Seres Therapeutics (NASDAQ:MCRB) Issues Earnings Results

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported ($1.76) earnings per share for the quarter, beating analysts...

Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday

Seres Therapeutics (NASDAQ:MCRB) will be releasing its Status update earnings before the market opens on Thursday, March 12. (View Earnings Report at...

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average - What's Next?

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average - Should You Sell...

Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization.</li><li>The company said following the pause in additional investment into the SER-155 Phase 2 study, it will shift its operational focus to high-value earlier-stage pipeline programs.</li><li>Seres noted that its cost-cutting measures are expected to extend its cash runway into the third quarter of 2026.</li></ul>Seres Therapeutics Inc. (MCRB) shares fell more than 21% in Thursday’s pre-market trade after the company announced that it is pausing a planned Phase 2 study, while reducing the headcount by 30% to extend its cash runway.Seres stated that it has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the U.S. Food and Drug Administration (FDA).“As we pursue earlier stage programs with the greatest opportunity, such as those targeting inflammatory bowel disease (IBD), we are exploring collaborations to provide additional capital to the company,” said Thomas DesRosier and Marella Thorell, co-CEOs of Seres.<h2 class="st-heading-2">Why Did Seres Pause The Study?</h2>Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization, adding that the Phase 2 study drug substance has already been manufactured.The company said that following the pause in additional investment into the SER-155 Phase 2 study, it will shift its operational focus to high-value earlier-stage pipeline programs. At the same time, it will continue to seek funding for the Phase 2 study, Seres said.<h2 class="st-heading-2">Extending Cash Runway</h2>Seres noted that its cost-cutting measures, including workforce reductions, are expected to extend its cash runway into the third quarter (Q3) of 2026.The company said that this will help in supporting the continued development of its programs for inflammatory and immune-related diseases, while also giving it additional time to secure funding for the SER-155 Phase 2 study.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MCRB">Seres Therapeutics</a> trended in the ‘bullish’ territory at the time of writing, with message volumes at ‘high’ levels.One user on Stocktwits said that Seres’ announcement confirms that “there is no one interested to partner” with the company.<stembedurl>https://stocktwits.com/Kenny1207/message/644771398</stembedurl><a href="https://stocktwits.com/symbol/MCRB">MCRB stock</a> is down 51% year-to-date and 75% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/samsung-ships-world-first-commercial-hbm4-memory-module-ai-computing/cZRTlXNR4ra">Samsung Ships First Commercial HBM4 Memory Module, Nvidia’s Vera Rubin Expected To Use It: SSNLF Stock Soars 55%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Seres Therapeutics biotechnology company building, Cambridge, Massachusetts, USA

MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30%

The company said that it will continue to seek funding for the SER-155 Phase 2 study.

Equity

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average - Time to Sell?

Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below Fifty Day Moving Average - Here's What Happened...

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average - Here's What Happened

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average - Here's What Happened...

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average - Time to Sell?

Seres Therapeutics (NASDAQ:MCRB) Share Price Passes Below 50-Day Moving Average - What's Next...

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average - Here's Why

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50-Day Moving Average - Here's Why...

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$1.82	--	--	N/A
Q4 '25	-$2.11	-$1.78	15.64%	BEAT
Q3 '25	$0.46	$0.94	105.84%	BEAT
Q2 '25	-$2.49	-$2.27	8.84%	BEAT
Q1 '25	$0.10	$3.75	3575.46%	BEAT

MCRB
Seres Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest MCRB News

MCRBSeres Therapeutics Inc